JUVE-BASIS Baricitinib in JIA Phase 3 RCT wk12 Cs or BioDMARDs IR ⚡️Time to disease flare HR 0.24 ⚡️JIA-ACR50% 63% ⚡️% flares 17% vs. 50% in PBO Safety profile similar than adults @RheumNow #EULAR2022 LB0002 https://t.co/dX3DpB4QHT